hit counter
bluebird bio, Inc. (BLUE) Stock News Sentiment & Price - Sentifly
BLUE - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



bluebird bio, Inc. (BLUE)

USA
Biotechnology
NASDAQ
BLUE Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
BLUE Latest news
The Motley Fool
Positive
Could This Beaten-Down Biotech Stock Be the Next Buyout Target?
13 hours ago

This gene-therapy specialist may need some help turning things around.

Business Wire
Neutral
bluebird bio Sets Record Date and Distribution Date for Planned Business Separation
2021-10-18 09:00

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that October 19, 2021 has been set as the record date for the dividend of shares of common stock of 2seventy to be distributed to bluebird stockholders in order to effect the separation of bluebird bio and 2seventy bio, Inc. into two independent, publicly traded companies. Each bluebird bio stockholder of record as of the close of business on October 19, 2021 will receive, on the distribution date, one share of

Zacks Investment Research
Neutral
bluebird (BLUE) Gives Details on Oncology Business Spinoff
2021-10-12 10:58

bluebird (BLUE) provides information on stock distribution ratio and cash allocation for the planned spin-off of the oncology business.

The Motley Fool
Neutral
Bluebird Bio or Heron Therapeutics: Which Stock Is the Better Comeback Play?
2021-10-11 10:00

These once-promising biotech stocks are trading at a fraction of their all-time highs right now.

Business Wire
Neutral
bluebird bio Provides Update on Upcoming Planned Business Separation
2021-10-08 16:54

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced the filing by 2seventy bio of an updated Form 10 Registration Statement with the U.S. Securities and Exchange Commission (SEC). This Form 10 reflects bluebird bio's plans for a tax-free spin-off of its oncology programs and portfolio into 2seventy bio as a publicly traded company. The spin-off is on track to be completed by early November 2021. bluebird bio also announced the appointment of Najoh Tita-Reid and

Zacks Investment Research
Neutral
bluebird (BLUE) Submits BLA for Gene-Therapy to Treat Thalassemia
2021-09-22 13:49

bluebird (BLUE) files BLA with the FDA for its gene therapy, betibeglogene autotemcel (beti-cel), in patients with transfusion-dependent ??-thalassemia.

Benzinga
Positive
Bluebird Bio Files US Application For ?-thalassemia Gene Therapy
2021-09-22 07:03

Bluebird Bio Inc (NASDAQ: BLUE) completed the rolling submission of its marketing application to the FDA seeking approval for betibeglogene autotemcel (beti-cel) gene therapy. The application covers adult, adolescent, and pediatric patients with ?-thalassemia who require regular red blood cell (RBC) transfusions across all genotypes.

Business Wire
Neutral
bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With ?-thalassemia Who Require Regular Red Blood Cell Transfusions
2021-09-21 16:15

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (Nasdaq: BLUE) today announced it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for betibeglogene autotemcel (beti-cel) gene therapy in adult, adolescent and pediatric patients with ?-thalassemia who require regular red blood cell (RBC) transfusions, across all genotypes. The FDA previously granted beti-cel Orphan Drug status and Breakthrough Therapy designation

InvestorPlace
Positive
7 Gene Editing Stocks Promising to Change our DNA
2021-09-15 12:45

Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market. The post 7 Gene Editing Stocks Promising to Change our DNA appeared first on InvestorPlace.

Business Wire
Neutral
2seventy bio Announces Upcoming Investor Events
2021-09-13 08:00

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, the planned oncology spin-off of bluebird bio (NASDAQ: BLUE) announced today that it will host a series of investor events to share further detail on its research pipeline and strategy. Session One: An Introduction to 2seventy's Pipeline; focus on AML [DARIC33] and Next-Gen Multiple Myeloma Strategy September 21, 2021, 11:00am-12:00pm ET Session Two: Focus on bNHL [bbT369] and Solid Tumor Strategy September 22, 2021, 1:00-2:00pm ET To access the

Loading more news...